Results 51 to 60 of about 72,428 (200)

Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights

Antioxidants, 2022
This study investigated the therapeutic effects of the phytochemical crocin alone or in combination with sorafenib both in rats chemically induced with hepatocellular carcinoma (HCC) and in human liver cancer cell line (HepG2).
Suzan B. S. Abdu, Nouf Juaid, A. Amin, M. Moulay, N. Miled   +4 more
semanticscholar   +1 more source

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats

Molecules, 2017
Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). In Asia, patients with HCC are potentially treated with the combination of sorafenib and Chinese herbal medicines to improve the efficiency and reduce the side ...
Chin-Tsung Ting, Yung-Yi Cheng, Tung-Hu Tsai   +2 more
doaj   +1 more source

Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.

PLoS ONE, 2021
Background and aimAs a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems.
Luping Gao, Yuji Morine, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki, Mitsuo Shimada   +8 more
doaj   +1 more source

Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma

Acta Pharmacologica Sinica, 2022
Sorafenib, which inhibits multiple kinases, is an effective frontline therapy for hepatocellular carcinoma (HCC). Ferroptosis is a form of iron-dependent programmed cell death regulated by lipid peroxidation, which can be induced by sorafenib treatment ...
Lu Zhang, Xian-Meng Li, Xu-He Shi, Kai Ye, Xue-li Fu, Xue Wang, Shiwei Guo, Jia-Qi Ma, Fei-fei Xu, Huiyun Sun, Qian-Qian Li, Weiying Zhang, L. Ye   +12 more
semanticscholar   +1 more source

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Signal Transduction and Targeted Therapy, 2020
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we
Junjie Xu, Lin Ji, Yuelong Liang, Zhe Wan, Wei Zheng, Xiaomin Song, Kirill Gorshkov, Qiming Sun, Hui Lin, Xue-Yong Zheng, Jiang Chen, Ren’an Jin, X. Liang, X. Cai   +13 more
semanticscholar   +1 more source

PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis

Cell Death and Disease, 2022
Phosphoglycerate kinase 1 (PGK1) has complicated and multiple functions in cancer occurrence, tumor progression and drug resistance. Sorafenib is the first-line treatment targeted drug for patients with kidney renal clear cell carcinoma (KIRC) as a ...
Yu He, Xixi Wang, Weiliang Lu, Dan Zhang, Lan Huang, Yang Luo, Li Xiong, Haocheng Li, Peng Zhang, Qiu Li, S. Liang   +10 more
semanticscholar   +1 more source

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031

Journal of Clinical Oncology, 2022
PURPOSE High allelic ratio (HAR) FLT3/ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy of adding sorafenib, a multikinase tyrosine kinase inhibitor to standard ...
J. Pollard, T. Alonzo, R. Gerbing, P. Brown, E. Fox, John Choi, B. Fisher, B. Hirsch, S. Kahwash, K. Getz, J. Levine, L. Brodersen, M. Loken, S. Raimondi, Katherine Tarlock, A. Wood, L. Sung, E. Kolb, A. Gamis, S. Meshinchi, R. Aplenc   +20 more
semanticscholar   +1 more source

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC

Molecular Cancer
Background and aims Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance.
Y. Chan, Junyu Wu, Yuanjun Lu, Qiucheng Li, Z. Feng, Lin Xu, Hongchao Yuan, Tingyuan Xing, Cheng Zhang, H. Tan, Yibin Feng, Ning Wang   +11 more
semanticscholar   +1 more source

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

JAMA Network Open, 2021
Key Points Question Compared with sorafenib, is atezolizumab plus bevacizumab cost-effective as first-line treatment of unresectable hepatocellular carcinoma?
D. Su, Bin Wu, Lizheng Shi
semanticscholar   +1 more source

Sorafenib-induced acute pancreatitis

Journal of Medical Sciences, 2014
Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade
Han-En Wang, Chun-Ting Chen, Hsin-Hung Huang   +2 more
doaj   +1 more source